Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial
出版年份 2018 全文链接
标题
Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial
作者
关键词
-
出版物
Journal for ImmunoTherapy of Cancer
Volume 6, Issue 1, Pages -
出版商
Springer Nature America, Inc
发表日期
2018-10-23
DOI
10.1186/s40425-018-0424-9
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study
- (2017) Andrea B. Apolo et al. JOURNAL OF CLINICAL ONCOLOGY
- Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma
- (2016) Siyuan Zheng et al. CANCER CELL
- Burden of Nonsynonymous Mutations among TCGA Cancers and Candidate Immune Checkpoint Inhibitor Responses
- (2016) Leandro M. Colli et al. CANCER RESEARCH
- Malignant Mesothelioma Effusions Are Infiltrated by CD3 + T Cells Highly Expressing PD-L1 and the PD-L1 + Tumor Cells within These Effusions Are Susceptible to ADCC by the Anti–PD-L1 Antibody Avelumab
- (2016) Swati Khanna et al. Journal of Thoracic Oncology
- Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study
- (2016) Corey J Langer et al. LANCET ONCOLOGY
- Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial
- (2016) Howard L Kaufman et al. LANCET ONCOLOGY
- PD-1/PD-L1 inhibitors
- (2015) Joel Sunshine et al. CURRENT OPINION IN PHARMACOLOGY
- Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study
- (2015) Martin Fassnacht et al. LANCET ONCOLOGY
- Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells
- (2015) B. Boyerinas et al. Cancer Immunology Research
- Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study
- (2015) André P Fay et al. Journal for ImmunoTherapy of Cancer
- The VEGF Inhibitor Axitinib Has Limited Effectiveness as a Therapy for Adrenocortical Cancer
- (2014) Ciara O'Sullivan et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma
- (2013) A Naing et al. BRITISH JOURNAL OF CANCER
- Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
- (2012) Suzanne L Topalian et al. CURRENT OPINION IN IMMUNOLOGY
- Sunitinib in Refractory Adrenocortical Carcinoma: A Phase II, Single-Arm, Open-Label Trial
- (2012) Matthias Kroiss et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Combination Chemotherapy in Advanced Adrenocortical Carcinoma
- (2012) Martin Fassnacht et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase II study of weekly paclitaxel and sorafenib as second/third-line therapy in patients with adrenocortical carcinoma
- (2011) Alfredo Berruti et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Current and Emerging Therapies for Advanced Adrenocortical Carcinoma
- (2011) L. J. Tacon et al. ONCOLOGIST
- Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study
- (2010) Paola Sperone et al. ENDOCRINE-RELATED CANCER
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- (2009) J. D. Wolchok et al. CLINICAL CANCER RESEARCH
- Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma
- (2009) Sebastian Wortmann et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Treatment of Advanced Adrenocortical Carcinoma with Erlotinib plus Gemcitabine
- (2008) Marcus Quinkler et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More